Catalyst
Slingshot members are tracking this event:
Lexicon (LXRX) Expects inTandem3 Data Mid-Year Evaluating Sotagliflozin in Type 1 Diabetes
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LXRX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2017
Occurred Source:
http://www.lexpharma.com/media-center/news/637-lexicon-pharmaceuticals-reports-positive-top-line-results-in-phase-3-intandem-3-study-for-sotagliflozin-in-patients-with-type-1-diabetes
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Intandem3, Sotagliflozin, Type 1 Diabetes
